[Recombinant human erythropoietin (KRN5702) therapy for autologous blood transfusion in patients with rheumatoid arthritis undergoing joint replacement surgery--a multicenter phase II clinical trial].

Saikawa, I; Sugioka, Y; Hotokebuchi, T; Tsutsui, H; Inaba, S; Takagishi, K; Iwata, H; Ogawa, R; Kondo, M; Ogata, K

Saikawa, I; Sugioka, Y; Hotokebuchi, T; Tsutsui, H; Inaba, S; Takagishi, K; Iwata, H; Ogawa, R; Kondo, M; Ogata, K.

Affiliation

Saikawa I; Department of Orthopedic Surgery, Faculty of Medicine, Kyushu University, Fukuoka-city.

Ryumachi ; 34(3): 583-93, 1994 Jun.

Article in Ja | MEDLINE | ID: mdl-8052924

Subject(s)

Arthritis, Rheumatoid/surgery; Blood Transfusion, Autologous; Erythropoietin/therapeutic use; Joint Prosthesis; Adult; Aged; Female; Humans; Japan; Male; Middle Aged; Recombinant Proteins/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Hemoterapia Main subject: Arthritis, Rheumatoid / Blood Transfusion, Autologous / Erythropoietin / Joint Prosthesis Type of study: Clinical_trials Country/Region as subject: Asia Language: Ja Journal: Ryumachi Year: 1994 Type: Article

Search on Google

Add to My VHL

XML

PubMed Links